ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Merry, A. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Merry, A. F.
Related Collections
Right arrow Cardiac - pharmacology

Ann Thorac Surg 2007;84:840
© 2007 The Society of Thoracic Surgeons

Original Articles: Cardiovascular

Invited commentary

Alan F. Merry, MB ChB, FANZCA

Department of Anesthesiology, University of Auckland, Private Bag 92019, Auckland, New Zealand 1003

(Email: a.merry@auckland.ac.nz).

The first 20% of the full text of this article appears below.

This study [1] adds to the confidence clinicians can have in the direct thrombin inhibitor bivalirudin as an anticoagulant for off-pump coronary artery bypass (OPCAB) surgery when heparin is contraindicated. Anticoagulation for cardiac surgery in patients with heparin-induced thrombocytopenia (HIT) or thrombotic syndrome (TS) is particularly difficult. It is becoming increasingly apparent that the direct thrombin inhibitor bivalirudin has considerable merit as an alternative to heparin in this situation. However . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2007 by The Society of Thoracic Surgeons.